RALBP1 and breast cancer: Among patients of the METABRIC breast cancer study, Rlip mutations were not observed and homozygous deletion of RALBP1 was exceedingly rare (0.09% of patients), supporting the importance of normally functioning Rlip protein in oncogenic processes [12].